Cargando…

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors

Current therapies for metastatic melanoma (anti-PD1 and BRAF/MEK inhibitors) can cause drug-induced vitiligo. The aim of this study is to dermatologically define and histologically characterize this new type of vitiligo, and assess the clinical course of the disease. Fourteen patients with metastati...

Descripción completa

Detalles Bibliográficos
Autores principales:	RAMONDETTA, Alice, RIBERO, Simone, CONTI, Luca, FAVA, Paolo, MARRA, Elene, BROGANELLI, Paolo, CALIENDO, Virginia, PICCIOTTO, Franco, GUIDA, Michele, FIERRO, Maria Teresa, QUAGLINO, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2020
Materias:	Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128901/ https://www.ncbi.nlm.nih.gov/pubmed/31532537 http://dx.doi.org/10.2340/00015555-3319

Ejemplares similares

A Case of a Pigmented Epithelioid Melanocytoma on a Mucosal Site
por: Ramondetta, Alice, et al.
Publicado: (2020)

In Vivo Observation of Cutaneous Larva Migrans by Fluorescence-Advanced Videodermatoscopy
por: Ramondetta, Alice, et al.
Publicado: (2021)

In Vivo Observation of Trombiculosis with Fluorescence–Advanced Videodermatoscopy
por: Ramondetta, Alice, et al.
Publicado: (2020)

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit
por: Quaglino, Pietro, et al.
Publicado: (2021)

Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience
por: Cariti, Caterina, et al.
Publicado: (2021)

SPECT/CT-Guided Surgical Removal of a Positive External Iliac Sentinel Node in Primary Umbilical Melanoma: Report of a Case, and Up-to-Date Review of the Literature
por: Picciotto, Franco, et al.
Publicado: (2022)

Sentinel Lymph Node Biopsy in Malignant Melanoma of the Head and Neck: A Single Center Experience
por: Rubatto, Marco, et al.
Publicado: (2023)

Treatment of Advanced Metastatic Melanoma
por: Quaglino, Pietro, et al.
Publicado: (2021)

Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients
por: Picciotto, Franco, et al.
Publicado: (2021)

Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy
por: Consoli, Francesca, et al.
Publicado: (2019)

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
por: Quaglino, Pietro, et al.
Publicado: (2021)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality
por: Ribero, Simone, et al.
Publicado: (2016)

Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021)

Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials
por: Amabile, Simone, et al.
Publicado: (2021)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

Time to next treatment and safety assessment in cutaneous‐T‐cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
por: Tian, Jun, et al.
Publicado: (2023)

Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study
por: Quaglino, Pietro, et al.
Publicado: (2022)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study
por: Amabile, Simone, et al.
Publicado: (2022)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o2pp3unnqsvsacckd65v33b135